BACKGROUND/AIM: Bendamustine hydrochloride (BH) is a key therapeutic agent for mantle cell lymphoma (MCL), while the mechanism underlying BH-resistance has not been verified. MATERIALS AND METHODS: We compared molecular/biological characteristics of a newly-generated MCL-derived cell line KPUM-YY1 and its BH-resistant subline KPUM-YY1R. RESULTS: The growth-inhibitory IC50 for BH was 20 μM in KPUM-YY1 cells, while cell proliferation was not inhibited by up to 60 μM BH in KPUM-YY1R cells. Compared to KPUM-YY1 cells, gene expression profiling in KPUM-YY1R cells revealed up-regulation of 312 genes, including ABCB1 encoding P-glycoprotein (P-gp), and microsomal glutathione S-transferase 1 (MGST1). Addition of either a P-gp inhibitor or a GST inhibitor, at least partly, restored sensitivity to BH in KPUM-YY1R cells. In addition, KPUM-YY1R cells showed cross-resistance against various anti-MCL chemotherapeutics. CONCLUSION: BH resistance is mediated by overlapping mechanisms with overexpression of ABCB1 and MGST1, and is potentially accompanied by multidrug resistance in MCL. Copyright
BACKGROUND/AIM: Bendamustine hydrochloride (BH) is a key therapeutic agent for mantle cell lymphoma (MCL), while the mechanism underlying BH-resistance has not been verified. MATERIALS AND METHODS: We compared molecular/biological characteristics of a newly-generated MCL-derived cell line KPUM-YY1 and its BH-resistant subline KPUM-YY1R. RESULTS: The growth-inhibitory IC50 for BH was 20 μM in KPUM-YY1 cells, while cell proliferation was not inhibited by up to 60 μM BH in KPUM-YY1R cells. Compared to KPUM-YY1 cells, gene expression profiling in KPUM-YY1R cells revealed up-regulation of 312 genes, including ABCB1 encoding P-glycoprotein (P-gp), and microsomal glutathione S-transferase 1 (MGST1). Addition of either a P-gp inhibitor or a GST inhibitor, at least partly, restored sensitivity to BH in KPUM-YY1R cells. In addition, KPUM-YY1R cells showed cross-resistance against various anti-MCL chemotherapeutics. CONCLUSION:BH resistance is mediated by overlapping mechanisms with overexpression of ABCB1 and MGST1, and is potentially accompanied by multidrug resistance in MCL. Copyright
Authors: N Kakazu; M Taniwaki; S Horiike; K Nishida; T Tatekawa; M Nagai; T Takahashi; T Akaogi; J Inazawa; M Ohki; T Abe Journal: Genes Chromosomes Cancer Date: 1999-12 Impact factor: 5.006
Authors: Tadeusz Robak; Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira; Johannes Drach; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi van de Velde; Franco Cavalli Journal: N Engl J Med Date: 2015-03-05 Impact factor: 91.245
Authors: M Taniwaki; G A Sliverman; K Nishida; S Horiike; S Misawa; C Shimazaki; I Miura; M Nagai; M Abe; S Fukuhara Journal: Blood Date: 1995-08-15 Impact factor: 22.113
Authors: Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams; Richard H van der Jagt; Jennifer W Oliver; Bruce D Cheson Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245